Navigation Links
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Date:3/31/2008

er stopping their current high blood pressure medication, patients received a single-pill combination of either Lotrel or a combination of benazepril and HCTZ. In the first two months of the study, doses of study medications were increased. Patients in the Lotrel arm started on 5/20 mg. The dose was increased to Lotrel 5/40 mg and, for patients not at goal blood pressure, then to 10/40 mg. Patients taking benazepril and HCTZ started at 20/12.5 mg and were increased to 40/12.5 mg and, for patients not at goal blood pressure, to 40/25 mg. The combination doses of benazepril and HCTZ 40/12.5 mg and 40/25 mg used in this study were investigational. In both arms, patients were given additional blood pressure medication if goal blood pressure was not attained on the maximum dose of study medications.

The primary study endpoint was a composite of cardiovascular disease, non- fatal heart attack, non-fatal stroke, and hospitalization for unstable angina (chest pain that occurs when the heart muscle does not get enough blood) or revascularization (a procedure that re-establishes blood flow to previously restricted regions of the heart), and cardiovascular death. The full data will be available later this year and further analyses will examine the effects on specific patient populations.

Important safety information

LOTREL and the fixed dose combination of benazepril and HCTZ are prescription medications for the treatment of high blood pressure. They should not be used before other high blood pressure medications have been tried first.

LOTREL and the fixed dose combination of benazepril and HCTZ can harm an unborn baby and even cause death. If you get pregnant, stop taking LOTREL or the benazepril and HCTZ combination. Call your doctor right away. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant.

Don't take LOTREL or the benazepril and HCTZ combination if you are allergic to any of the ingredien
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
4. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
5. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. New Drug Combination is Able to Eradicate Breast Metastases in Mice
9. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 2Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 3Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2Pro active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 62183 1Pro active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 62183 2Pro active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 62183 3Pro active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 62183 4Diabetes cases to double and costs to triple by 2034 62179 1Diabetes cases to double and costs to triple by 2034 62179 2Diabetes cases to double and costs to triple by 2034 62179 3Ecologists sound out new solution for monitoring cryptic species 10909 1Ecologists sound out new solution for monitoring cryptic species 10909 2
Breaking Medicine News(10 mins):Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 3Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 4Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 2Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 4Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4Health News:New study finds low rate of injuries at overnight summer camp 2